Jazz Pharma's Ziihera Earns FDA Nod for Gastric Cancer

Jazz Pharmaceuticals receives FDA approval for Ziihera (zanidatamab-hrii) as the first new HER2-targeted gastric cancer therapy in over 15 years, setting a new survival benchmark.

Lead

A New Survival Benchmark in HER2+ Gastric Cancer

Ziihera's approval covers its use in combination with the PD-1 checkpoint inhibitor tislelizumab and chemotherapy, a three-drug regimen that delivered median overall survival of more than 26 months in the pivotal clinical trial. That figure represents a meaningful advance over outcomes seen with prior standard-of-care regimens in HER2-positive gastroesophageal adenocarcinoma, a molecularly defined subset accounting for roughly 15 to 20 percent of all gastric and gastroesophageal junction cancers diagnosed annually.

Zanidatamab-hrii is a bispecific antibody engineered to bind two distinct epitopes on the HER2 receptor simultaneously, a mechanism designed to produce more complete and durable HER2 blockade than single-domain agents. The addition of tislelizumab to the regimen reflects the established paradigm of combining HER2-directed therapy with immunotherapy across gastrointestinal oncology, an approach that has reshaped treatment algorithms in breast and colorectal cancer over the preceding decade.

Why Does This Approval Reshape the Competitive Landscape?

The FDA's decision resets the standard of care in first-line HER2+ gastroesophageal adenocarcinoma, a setting where trastuzumab-based therapy had remained the backbone for more than 15 years. A median overall survival exceeding 26 months positions Ziihera (zanidatamab-hrii) as one of the most clinically significant advances in gastric cancer in the modern treatment era.

The approval also reinforces Jazz Pharmaceuticals' oncology expansion strategy. The company, historically anchored in sleep and central nervous system disorders, has pursued an aggressive build-out in cancer through licensing agreements and pipeline investment. Ziihera had already secured FDA approval in biliary tract cancer; the first-line gastroesophageal indication substantially expands the drug's addressable patient population in the United States. Biotech cancer stocks broadly tracked the approval as a signal of growing momentum in HER2-targeted oncology, a category drawing increasing commercial and clinical attention across multiple tumor types.

What Comes Next for Jazz Pharmaceuticals?

Commercial launch in the first-line gastroesophageal setting is expected to begin in the near term, with payer negotiations and formulary placement shaping the pace of real-world adoption. Jazz Pharmaceuticals faces a competitive backdrop that includes pembrolizumab-based combinations in gastric cancer, though zanidatamab-hrii's bispecific mechanism and 26-month survival data establish a clinically distinct profile.

Global regulatory submissions, including in the European Union, are anticipated as Jazz moves to maximize the international opportunity across Ziihera's approved and late-stage pipeline indications. The HER2-positive gastric cancer label also opens the door to combination studies that pair zanidatamab-hrii with additional novel agents, a priority as the company builds out its oncology franchise.

Outlook

The FDA's approval of Ziihera (zanidatamab-hrii) in combination with tislelizumab and chemotherapy closes a 15-year treatment gap in HER2-positive gastroesophageal adenocarcinoma and delivers a median overall survival benchmark - exceeding 26 months - that sets a new clinical bar. Jazz Pharmaceuticals now faces the execution challenge of converting strong trial data into durable commercial performance in a competitive oncology market.